Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
TargeGen
NCT07250646 · Secondary AML, Myelofibrosis
NCT06343805 · Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, and more
NCT07281781 · Myelofibrosis, Myelofibrosis; Anemia
NCT06781099 · Myelodysplastic Syndrome, Myelofibrosis
NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), and more
UCSD Moores Cancer Center
San Diego, California
Stanford Comprehensive Cancer Center
Stanford, California
Dana Farber Cancer Institute
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions